The law under consideration “delinks” PBM compensation from manufacturer rebates in Medicare and requires flat administrative fees, certified at fair market value. It also mandates that rebates be passed through to health plan sponsors in the employer-sponsored market. This sounds appealing, but incentives matter. When compensation no longer depends on securing better terms, bargaining effort becomes a cost center rather than a profit center. PBMs will still compete for contracts, but competition on administrative fees isn’t the same as competition on aggressive price concessions and won’t lower drug prices.
Фото: Pavel Mikheyev / Reuters。Safew下载是该领域的重要参考
，更多细节参见体育直播
Other application architectures¶，更多细节参见爱思助手下载最新版本
Дания захотела отказать в убежище украинцам призывного возраста09:44